Lupin has received final approval from the US health
regulator for marketing Norgestimate and Ethinyl Estradiol tablets, used
for the prevention of pregnancy, in the US market.
The
company has received final approval from the United States Food and
Drug Administration (USFDA) to market its Norgestimate and Ethinyl
Estradiol tablets USP, 0.25 mg/0.035 mg, Lupin said in a filing to BSE.
The company’s product is a generic version of Janssen Pharmaceuticals Inc’s Ortho-Cyclen 28 tablets, it added.
No comments:
Post a Comment